2022 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2022-04-16±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : º¤½ºÄÚ Á¦1ȸÀÇÀå
±³À°ÁÖÁ¦ :
2022 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼ºÀÎALL¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í Äڷγª·Î »çÀüµî·ÏÀÌ Á¶±â ¸¶°¨µÉ¼ö ÀÖÀ½
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 10:00~10:30 B-ALL(Acute Lymphoblastic Leukemia): Updated practices ÀÓ¼º³²(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 10:30~11:00 T-ALL(Acute Lymphoblastic Leukemia) : Updated practices ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 11:00~11:30 Pathophysiology and biomarkers in ALL(Acute Lymphoblastic Leukemia ) ±è¹Ì¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 11:30~12:00 Novel therapeutics in ALL(Acute Lymphoblastic Leukemia) Çã¹ÌÈ(°è¸íÀÇ´ë)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 13:00~14:00 Newest technology in T-cell engineering for lymphoid malignancy ±èÂùÇõ(Çѱ¹°úÇбâ¼ú¿ø)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 14:00~14:30 Insights on minimal residual disease measurement ¾È¾Æ¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-16 Á¦1ȸÀÇÀå 14:30~15:00 MRD based ALL(Acute Lymphoblastic Leukemia ) treatment °í¿µÀÏ(¼¿ïÀÇ´ë)